Kodak unveils $500M Pension Asset Reversion Plan to Boost U.S. Drug Production

Management Highlights and Strategic Focus

During the earnings call for Eastman Kodak Company (KODK) in Q2 2025, CEO Jim Continenza emphasized the company's continued execution of its long-term plan despite global uncertainties. He highlighted the importance of deleveraging the business and strengthening the balance sheet. This focus includes investments in growth areas such as film, electric vehicle battery substrate coating, and a newly launched medical group.

Continenza also pointed to positive momentum in the Advanced Materials and Chemicals (AMC) division, stating that these investments are beginning to yield results. The company remains committed to U.S. manufacturing, with operations spanning from Rochester to the production of motion picture and still film, digital printers, ink, and chemicals. Additionally, Kodak is the only manufacturer of lithographic plates in the United States.

Expansion into Pharmaceuticals and New Facilities

A key initiative within the AMC division is the establishment of a new cGMP pharmaceutical manufacturing facility in Rochester. This facility has been registered with the FDA and is certified to produce and sell certain regulated pharmaceutical products. It will initially focus on producing phosphate buffered saline (PBS) for laboratory use, with plans to expand into more complex injectables like IV saline.

On the topic of tariffs, Continenza noted that year-to-date, they have not had a material impact on the business. However, he expressed support for tariffs that benefit U.S. manufacturers.

Financial Developments and Pension Assets

The CFO, David Edward Bullwinkle, provided an update on the KRIP termination and settlement process. He stated that the company estimates approximately $500 million in pension assets will revert to Kodak by December 2025, with about $300 million in cash and the rest in illiquid assets such as hedge funds. These assets are currently in the redemption process.

Bullwinkle also mentioned the exchange of Series C preferred stock held by Grand Oaks Capital for common stock at $8.25 per share. This move eliminates the entire $100 million in outstanding Series C preferred stock, which had a mandatory redemption date of May 28, 2026, along with over $24 million in accrued paid-in-kind dividends.

However, the company disclosed in its Form 10-Q filing that there is substantial doubt about its ability to continue as a going concern.

Outlook and Future Plans

Management reiterated that the KRIP asset reversion is expected to provide around $500 million by December 2025, with a significant portion allocated toward reducing term debt. The new pharmaceutical manufacturing facility is set to start with PBS and eventually expand into more advanced injectable products.

The company’s guidance remains consistent with previous quarters, focusing on deleveraging, U.S. manufacturing, and growth in the AMC division.

Financial Results and Performance

For Q2 2025, Kodak reported revenues of $263 million, slightly lower than the $267 million recorded in the same period in 2024. Gross profit for the quarter decreased by $7 million year-over-year, with a gross profit margin of 19%, down from 22% in Q2 2024.

Net loss for the quarter was $26 million, compared to net income of $26 million in the prior year. After accounting for a $17 million noncash asset impairment charge, the adjusted net loss was $9 million. Operational EBITDA for the quarter was $9 million, down from $12 million in the previous year.

At the end of the quarter, unrestricted cash balances stood at $155 million, reflecting a $46 million decrease from December 31, 2024. Despite this, there was improvement in cash usage compared to Q1 2025. The company remains in compliance with all financial covenants.

No Formal Q&A Session

There was no formal Q&A session during the call. The company stated that it would not be holding one and instead encouraged investors to reach out to the Investor Relations team for follow-up.

Sentiment and Management Tone

Analysts were unable to assess sentiment due to the absence of a Q&A session. However, management’s tone during the call was steady and focused on progress in growth initiatives, deleveraging, and U.S. manufacturing. They acknowledged ongoing challenges, including the going concern disclosure.

Compared to the previous quarter, the tone remained similar—optimistic about growth but cautious about liquidity risks and uncertainties.

Quarter-over-Quarter Comparison

Revenue for Q2 2025 was higher than Q1 2025 ($263 million vs. $247 million), with a flat gross profit percentage at 19%. Net loss increased from $7 million in Q1 to $26 million in Q2, partly due to a noncash asset impairment charge. Operational EBITDA rose from $2 million in Q1 to $9 million in Q2.

The strategic focus on the AMC business, U.S. manufacturing, and deleveraging remained consistent. Management’s confidence in executing the long-term plan stayed steady, with continued emphasis on addressing debt through the reversion of pension assets.

Risks and Concerns

The company faces significant risks, including uncertainty around its ability to continue as a going concern. This is tied to the maturity of Series B preferred stock and a term loan in May 2026. The company’s plan to use proceeds from the KRIP asset reversion to address these maturities is critical.

CFO Bullwinkle explained that because these plans are not fully within the company’s control, they are not deemed probable under U.S. GAAP rules, necessitating the going concern disclosure.

Other ongoing risks include global economic uncertainties, rising aluminum and manufacturing costs, and the need to generate additional liquidity.

Final Takeaway

Despite challenges, Kodak’s management highlighted progress in deleveraging, expansion of U.S.-based pharmaceutical manufacturing, and continued investment in growth businesses. While revenue and operational EBITDA improved sequentially, the company remains exposed to material risks related to debt maturities and liquidity. The planned $500 million KRIP asset reversion and its use to pay down debt remain crucial to Kodak’s financial outlook for the coming year.